Responses
Immune cell therapies and immune cell engineering
Original research
Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+ T cells activities after hematopoietic transplantation for blood malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.